QUALIS PHARMA SOLUTIONS LIMITED
Company number 13666794 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
QUALIS PHARMA SOLUTIONS LIMITED - Analysis Report
Company Number: 13666794
Analysis Date: 2025-07-19 13:05 UTC
Risk Rating: LOW
The company demonstrates positive net current assets and net assets with a consistent increase year on year. There are no overdue filings, liquidation, or administration indicators, and the micro-entity status limits complexity and reporting risk.Key Concerns:
- Absence of employees reported over multiple years may indicate heavy reliance on director or outsourced resources, potentially affecting operational scalability and resilience.
- The company is very young (incorporated 2021), so it lacks a long financial history to fully assess stability and performance trends.
- The financial statements are unaudited, which is typical for micro-entities but limits third-party assurance on reported figures.
- Positive Indicators:
- Net current assets increased substantially from £6,657 in 2023 to £19,161 in 2024, indicating improving liquidity and working capital position.
- Shareholders’ funds have grown in line with net assets, suggesting retained earnings or capital injections are strengthening equity.
- All statutory filings (accounts and confirmation statements) are up to date with no overdue notices, indicating good regulatory compliance.
- The sole director and 100% shareholder has been in place since incorporation, providing continuity of control.
- Due Diligence Notes:
- Verify the source of the increased current assets and whether these are cash or receivables, to confirm liquidity quality.
- Understand the business model and revenue generation given zero employees reported; assess sustainability and dependency on external contractors or director involvement.
- Confirm absence of contingent liabilities or off-balance-sheet risks not disclosed in the micro-entity accounts.
- Review any corporate governance policies or risk management practices given the sole director structure.
- Assess the impact of no audit on financial statement reliability, particularly since the accounts are prepared under micro-entity rules.
Sign in to generate a free AI analysis of this company — no password needed, just an email link.